Malignant diseases of the head and neck require radical treatment, often resulting in loss of the dentition and supporting structures, facial defects and drastic changes in anatomical form. The implications of this are life-changing, often associated with the loss or hindrance of function, speech, swallowing and appearance, leading to a detrimental effect on the patient's social and psychological wellbeing. Maxillary and mid-facial defects are complex and can be classified by level using classifications such as that by Brown and Shaw (2010) and Okay, Genden, Buchbinder, and Urken (2001) to assist in treatment planning, resection, surgical reconstruction and prosthodontic rehabilitation. In 1998, Professor PI Branemark's team developed the specifically designed zygomatic implant for use in compromised maxillary bone including severe atrophy, congenital defects and tumour resection defects (Brånemark, 1998). In 2001, his team published the first paper (Parel, Brånemark, Ohrnell, & Svensson, 2001) on the survival of these implants placed into the residual zygomatic